Revance Therapeutics Statistics
Total Valuation
REGENXBIO has a market cap or net worth of $412.68 million. The enterprise value is $273.48 million.
Important Dates
The next confirmed earnings date is Thursday, August 7, 2025, before market open.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
REGENXBIO has 50.39 million shares outstanding. The number of shares has increased by 14.92% in one year.
| Current Share Class | 50.39M |
| Shares Outstanding | 50.39M |
| Shares Change (YoY) | +14.92% |
| Shares Change (QoQ) | +1.11% |
| Owned by Insiders (%) | 8.00% |
| Owned by Institutions (%) | 73.64% |
| Float | 41.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.66 |
| Forward PS | 1.42 |
| PB Ratio | 1.50 |
| P/TBV Ratio | 1.51 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.75 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.93, with a Debt / Equity ratio of 0.49.
| Current Ratio | 2.93 |
| Quick Ratio | 2.82 |
| Debt / Equity | 0.49 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.17 |
Financial Efficiency
Return on equity (ROE) is -47.44% and return on invested capital (ROIC) is -20.30%.
| Return on Equity (ROE) | -47.44% |
| Return on Assets (ROA) | -17.56% |
| Return on Invested Capital (ROIC) | -20.30% |
| Return on Capital Employed (ROCE) | -40.96% |
| Revenue Per Employee | $443,960 |
| Profits Per Employee | -$446,711 |
| Employee Count | 353 |
| Asset Turnover | 0.28 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -42.53% in the last 52 weeks. The beta is 1.11, so REGENXBIO's price volatility has been higher than the market average.
| Beta (5Y) | 1.11 |
| 52-Week Price Change | -42.53% |
| 50-Day Moving Average | 8.92 |
| 200-Day Moving Average | 8.39 |
| Relative Strength Index (RSI) | 43.67 |
| Average Volume (20 Days) | 586,911 |
Short Selling Information
The latest short interest is 6.18 million, so 12.26% of the outstanding shares have been sold short.
| Short Interest | 6.18M |
| Short Previous Month | 6.13M |
| Short % of Shares Out | 12.26% |
| Short % of Float | 14.97% |
| Short Ratio (days to cover) | 7.90 |
Income Statement
In the last 12 months, REGENXBIO had revenue of $156.72 million and -$157.69 million in losses. Loss per share was -$3.10.
| Revenue | 156.72M |
| Gross Profit | 125.76M |
| Operating Income | -157.36M |
| Pretax Income | -241.23M |
| Net Income | -157.69M |
| EBITDA | -141.37M |
| EBIT | -157.36M |
| Loss Per Share | -$3.10 |
Full Income StatementBalance Sheet
The company has $267.87 million in cash and $133.53 million in debt, giving a net cash position of $139.20 million or $2.76 per share.
| Cash & Cash Equivalents | 267.87M |
| Total Debt | 133.53M |
| Net Cash | 139.20M |
| Net Cash Per Share | $2.76 |
| Equity (Book Value) | 274.20M |
| Book Value Per Share | 5.47 |
| Working Capital | 206.51M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$84.04 million and capital expenditures -$2.90 million, giving a free cash flow of -$86.94 million.
| Operating Cash Flow | -84.04M |
| Capital Expenditures | -2.90M |
| Free Cash Flow | -86.94M |
| FCF Per Share | -$1.73 |
Full Cash Flow StatementMargins
Gross margin is 80.24%, with operating and profit margins of -100.41% and -100.62%.
| Gross Margin | 80.24% |
| Operating Margin | -100.41% |
| Pretax Margin | -100.62% |
| Profit Margin | -100.62% |
| EBITDA Margin | -90.20% |
| EBIT Margin | -100.41% |
| FCF Margin | n/a |
Dividends & Yields
REGENXBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.92% |
| Shareholder Yield | -14.92% |
| Earnings Yield | -38.21% |
| FCF Yield | -21.07% |
Analyst Forecast
The average price target for REGENXBIO is $31.75, which is 287.67% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $31.75 |
| Price Target Difference | 287.67% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 51.92% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
REGENXBIO has an Altman Z-Score of -1.35 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.35 |
| Piotroski F-Score | 4 |
